BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Sierra Oncology Inc.

Headquarters: San Mateo, CA, United States of America
Website: N/A
Year Founded: 2004
Status: Acquired

BioCentury | Nov 11, 2023
Data Byte

After a second look, EMA’s CHMP recommends Mirati’s KRAS inhibitor 

CHMP’s November opinions include four new medicines and an expansion of Mounjaro’s label to include obesity
BioCentury | Oct 18, 2023
Data Byte

FDA’s NME approvals in September

Agency approved two new cancer and one new neuro drug; plus Amicus’ Pompe therapy among pair of approvals for rare metabolic disorders
BioCentury | Sep 15, 2023
Regulation

Sept. 15 Quick Takes: FDA approves GSK’s momelotinib, gained in $1.9B Sierra deal

Plus: Oral arguments in IRA suit consistent with briefs, and updates from Iovance and MAPS
BioCentury | Sep 6, 2023
Data Byte

11 PDUFA dates on FDA’s agenda in September

Decisions due this month include BioLineRx’s Aphexda, Roche’s subcutaneous Tecentriq and GSK’s momelotinib
BioCentury | Jun 16, 2023
Regulation

June 16 Quick Takes: Roche wins bispecific approval

Plus: FDA extends momelotinib’s review, and Neuvivo raises cash
BioCentury | Jun 1, 2023
Data Byte

At least 15 PDUFA dates on FDA’s calendar for June

Expected decisions include BioMarin’s hemophilia A gene therapy, a subQ form of argenx’s of myasthenia gravis drug, and Aldeyra’s retinal cancer candidate
BioCentury | Apr 19, 2023
Product Development

Gilead’s next steps in oncology

Ambitious top-10 goal in cancer by 2030, with BD focus on early-stage assets that add mechanisms to pipeline
BioCentury | Apr 18, 2023
Deals

Bellus’ focus on cough program pays off with $2B GSK buyout

Montreal biotech shed other programs, drove single asset through mid-stage trials to provoke takeout interest
BioCentury | Jan 9, 2023
Deals

CVRs address risks in billion-dollar AZ-CinCor, Ipsen-Albireo deals

Pair of high-premium M&A transactions could deliver shareholders more value tied to regulatory milestones
BioCentury | Oct 4, 2022
Management Tracks

Sause named CEO of Roche Diagnostics

Plus Kranzler becomes CEO of Urica, and updates from Pharus, Celularity, Cerevance and more
Items per page:
1 - 10 of 29